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Abstract: The mechanical reinforcement of the ventricular wall after a myocardial infarction has 
been shown to modulate and attenuate negative remodeling that can lead to heart failure. Strategies 
include wraps, meshes, cardiac patches, or fluid-filled bladders. Here, we review the literature 
describing these strategies in the two broad categories of global restraint and local reinforcement. 
We further subdivide the global restraint category into biventricular and univentricular support. 
We discuss efforts to optimize devices in each of these categories, particularly in the last five years. 
These include adding functionality, biomimicry, and adjustability. We also discuss computational 
models of these strategies, and how they can be used to predict the reduction of stresses in the heart 
muscle wall. We discuss the range of timing of intervention that has been reported. Finally, we give 
a perspective on how novel fabrication technologies, imaging techniques, and computational 
models could potentially enhance these therapeutic strategies. 
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1. Introduction and Rationale for Mechanical Reinforcement of the Left Ventricle Post-
Myocardial Infarction 
Over one million people suffer a myocardial infarction (MI), or heart attack in the U.S. every 
year [1]. An MI occurs when blood flow to a region of myocardium (heart muscle) is blocked, leading 
to cardiomyocyte death. The ischemic region, or infarct, loses its ability to contract, creating a 
mechanical disadvantage. Systolic function impairment can lead to the activation of compensatory 
mechanisms, pathological ventricular remodeling, and ultimately, heart failure (HF) [2]. 
For patients that survive an MI, preventing or hindering the development of HF is the main goal. 
Current clinical practices include medication and lifestyle changes in the post-MI stages. If patients 
progress to HF, left ventricular assistive devices (LVADs) can act as a bridge-to-transplant or a 
bridge-to-destination, but have inherent limitations, such as a propensity for thrombogenicity, and 
limited long-term success. Mechanical reinforcement strategies, where part or all of the heart is 
reinforced or restrained with an epicardially placed wrap or patch, have been proposed as promising 
therapeutic approaches. By supporting the diseased myocardium, these strategies can lead to an 
improved ventricular function by either preventing or hindering pathological left ventricle (LV) 
remodeling in the infarcted heart [3]. 
The epicardial restraint field was pioneered with cardiomyoplasty, a surgical procedure that 
aimed to restrain dilation and aid ejection in the failing heart by wrapping the epicardium with the 
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latissimus dorsi muscle (from the posterior trunk) and stimulating the wrap to contract. Clinical 
studies showed that the efficacy of this procedure relied on the passive restraint exerted by the wrap 
[4]. Although the procedure was abandoned, it motivated further exploration into passive restraint. 
Initial devices were targeted at physically constraining the LV and treating end-stage HF. These 
efforts were later refocused at the earlier intervention of attenuating LV dilation post-MI [5]. 
One of the widely studied hypotheses in recent years has been whether the localized mechanical 
reinforcement of the infarct can limit LV dilation or prevent a progression to HF by limiting infarct 
expansion in the short-term following a heart attack [5]. With the contiguous development of the 
regenerative medicine field, several variations of local restraint arose and range from tissue-
engineered or cell-seeded biomaterial patches to anisotropic reinforcement. For the purpose of this 
review, we limit our definition of local restraint to those devices, patches, or scaffolds—synthetic or 
naturally derived—that can exert a purely mechanical effect regardless of the presence of biological 
agents [5]. 
Constant improvements of this therapeutic strategy are being reported in the literature. 
Motivated by one of the key limitations associated with early mechanical global and local restraint 
devices or patches—the inability to adapt the level of restraint—adjustable and quantifiable 
ventricular restraint [6] has recently been studied, and computational modeling has been used to 
determine the patch mechanical properties for optimal local reinforcement [7,8]. This review will 
discuss how mechanical support strategies post-MI have evolved in recent years. Epicardial 
implantable devices or patches, developed prior to 2013, have been thoroughly discussed in 
comprehensive reviews [3,5], and this review will focus on reviewing and discussing more recent 
studies on (i) the global epicardial restraint of one or both ventricles and (ii) the local reinforcement 
of the infarct region (Figure 1). We discuss how technological advancements in recent years have 
addressed previous limitations associated with post-MI cardiac restraint and reinforcement. 
Nonepicardial approaches, such as ventricular restoration procedures, perivascular devices and 
reinforcement via intramyocardial injection of biomaterials are beyond the scope of this review and 
for reviews in these topics we direct the reader to other work [8–10]. 
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Figure 1. Visual representation of types of epicardial restraint and reinforcement devices including 
global restrain strategies (both ventricles and left ventricle (LV) only) and local reinforcement (infarct 
only). Images modified and reprinted from [8,11–19] with permission from Elsevier, Springer, Wolters 
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Kluwer Health, Inc., and Mary Ann Liebert, Inc., respectively. PEGSDA: Poly(ethylene glycol) 
sebacate diacrylate. 
To identify studies to be included in this review—those describing epicardially placed 
mechanical support strategies post-MI—a chronological review of literature databases (i.e., Google 
Scholar, PubMed, and Web of Science), was conducted from 2013 to the present. The keywords used 
as search entries were ‘ventricular restraint’. Only search results pertaining to the cardiovascular field 
were considered and further filtered by criteria such as the nature of epicardial placement including 
global or local mechanical support. 
2. Optimizing Biventricular Restraint Devices 
Table 1 summarizes preclinical chronic results of biventricular restraint devices. The most 
extensively studied are the Acorn CorCap (Acorn Cardiovascular, Inc.) and the ParaCor HeartNet 
(Paracor Medical) . The Acorn CorCap cardiac support device (CSD) is a mesh-like device made of 
knitted polyester that surrounds the heart [20]. The device is compliant and designed to provide 
greater diastolic support in the circumferential direction than in the apex-to-base direction. The CSD 
is first attached to the epicardium with a ring of sutures around the base of the heart, and then its two 
edges are sutured, creating a seam on the anterior wall. This allows for the adjustment of the CSD fit 
and allows a properly positioned device to bear enough of the end-diastolic load to reduce the degree 
of stretching and the magnitude of wall stress [20]. The CorCap’s efficacy to reduce or reverse the 
progression of heart failure was established with various ovine animal studies [21,22] and the 
subsequent demonstration of dilation prevention following an MI [23–25]. Promising results from 
preclinical testing led to a first-in-human safety study, where no device-related mortality was 
observed and improvements in the New York Heart Association (NYHA) classification and LV 
dilation were reported [26,27]. To follow, a multicenter randomized controlled trial initiated in 2004 
and showed improvements in LV size and shape in patients with the CSD five years post-
implantation. However, because the primary end-points of the trial were inconclusive (i.e., survival, 
changes in NYHA classification, or freedom from major cardiac procedures), the U.S. Food and Drug 
Administration (FDA) did not approve the device, primarily due to concerns of safety and efficacy 
[28,29].
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Table 1. Summary of chronic epicardial global restraint studies (those reviewed in [5] are not included). 
Type of 
Restraint 
Animal 
Infarct/HF 
Model 
Follow-
Up Time 
Post-MI 
Restraint Device or 
Patch Material 
EDV ESV EF 
S
V 
CO FS/FAS/WT dP/dt ESPVR Reference 
Global 
(both 
ventricles) 
Male 
Sprague 
Dawley rats 
LAD ligation 30 days 
ASD device 
(biocompatible silicone) 
+ BMSC 
- - - - - - ↑ - [30] 
Global 
(both 
ventricles) 
Male 
Sprague 
Dawley rats 
LAD ligation 30 days 
ASD device (silicone) + 
Salvia miltiorrhiza 
- - -  - - ↑ - [31] 
Global 
(both 
ventricles) 
Beagle dogs 
LAD diagonal 
ligation 
12 weeks 
Biodegradable 
polyglycolic acid suture 
knitted support device 
↔ 
↔, 
↓ ΔLVESV 
↑ 
LVEF 
 - - ↔ - 
[32] Nonbiodegradable 
polyethylene 
terephthalate suture 
knitted support device 
↔, 
↓ ΔLVEDV 
↔, 
↓ ΔLVESV 
↔ 
LVEF 
 - - ↔ - 
Global 
(both 
ventricles) 
Beagle dogs 
Posterior wall 
infarction by 
ligation of 
proximal/distal 
branches of left 
diagonal, obtuse 
marginal and 
posterior 
coronary arteries 
3 months 
CSD knitted dog mesh 
(polyester sutures) 
↔ ↔ ↑  - - - Emax ↑ [33] 
Global 
(both 
ventricles) 
Wistar rats LAD ligation 
15 days 
PEGSDA-coated 
polyanhydroglucuronic-
acid scaffold 
- - ↑  - - - - 
[16] 
Global 
(LV only) 
Wistar rats LAD ligation PEGSDA hydrogel - - ↑  - - - - 
ASD: Active hydraulic ventricle supporting drug delivery system; BMSC: Bone marrow derived stem cells; CO : Cardiac output; CSD: Cardiac support device; 
dP/dt: Rate of systolic pressure generation; Emax: End-systolic elastance; EDV: End-diastolic volume; EF: Ejection fraction; ESPVR: Slope of the end-systolic pressure–
volume relationship; ESV: End-systolic volume; FAS: Fractional area shortening; FS: Fractional shortening; HF: Hart failure; LAD: Left anterior descending coronary 
artery; LV: Left ventricle; LVEF: Left ventricular ejection fraction; LVESV: Left ventricular end-systolic volume; MI: Myocardial infarction; PEGSDA: Poly(ethylene 
glycol) sebacate diacrylate; SV: Stroke volume; WT: Wall thickening.↑: Increased; ↔: No change; ↓: Decreased. 
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The Paracor HeartNet CSD is a passive, biventricular restraint device consisting of a NiTinol 
wire mesh. It is designed to be flexible and elastic, to achieve a high degree of conformability to the 
heart when appropriately sized [13]. One benefit of the HeartNet is that the delivery system enables 
the implantation procedure to be less invasive than for other CSDs. Testing of the HeartNet in a 
canine HF model yielded encouraging results as hemodynamic parameters shifted back to pre-HF 
baseline over the course of the eight-week study. Prevention of dilation was observed in an ovine 
animal model of post-MI reinforcement six weeks after HeartNet implantation. Surprisingly, this did 
not translate to an improved cardiac function [34]. Initial safety and feasibility clinical testing of the 
HeartNet demonstrated low complication rates in 21 patients with NYHA II and III HF. This was 
followed by a 51-patient study which showed very promising improvements in cardiac function and 
no device morbidity. However, the major randomized, multi-institutional clinical trial with this 
device—Prospective Evaluation of Elastic Restraint to Lessen the Effects of Heart Failure (PEERLESS-
HF)—was suspended because primary efficacy outcomes at six months were not met and all-cause 
mortality at 12 months post-device implantation was similar between the HeartNet and control 
groups [13]. 
2.1. Adjustability 
One of the drawbacks of biventricular restraint is the possibility that the initial restraint level, 
while reinforcing the infarct region and preventing ventricular dilation, also inhibits diastolic filling. 
To address this, Ghanta et al. [12] developed a technique called quantitative ventricular restraint 
(QVR). This strategy is described by the implantation of a half ellipsoidal polyurethane balloon 
around both ventricles. The balloons are then inflated with saline to generate restraint, and the 
volume of saline in the reservoirs, and thus the level of restraint, can be modified through a 
subcutaneous port and indwelling catheter. By varying and optimizing the restraint level in an ovine 
animal model, they showed that improvements in cardiac output were achieved [35]. Later, the same 
group showed the effects of adjustable and measurable ventricular restraint (AMVR) on long-term 
LV remodeling [6], yielding the conclusion that the speed of reverse, positive remodeling increased 
with higher levels of restraint. 
2.2. Adding Functionality 
Following the validation of the aforementioned devices, the further optimization of ventricular 
support has been pursued. Efforts at enhancing this therapeutic strategy include the addition of 
functionality, the variation of the duration of restraint and the use of biomimetic materials to match 
the mechanical properties of heart muscle. For instance, in terms of added functionality, the 
validation of a new mechanism aiming to modulate diastolic filling was realized by Snowden et al. 
[36]. Further, Park et al. [37] developed an electric mesh that wraps around the heart to deliver 
electrical impulses to the entire ventricular myocardium. This wrap was constructed from silver 
nanowires embedded in a rubber polymer designed to conform to patient-specific three-dimensional 
(3D) anatomy. In a rat MI model, the group showed that the mesh exerts beneficial effects and 
integrates both structurally and electrically with the myocardium while preserving diastolic 
relaxation, reducing wall stress, and improving cardiac function. 
Another knitted biventricular device was shown to positively impact LV remodeling and mitral 
regurgitation following MI creation. Okada et al. [33] report CSDs produced by a computer-assisted 
knitting machine (Shimaseiki Co., Wakayama, Japan) with two 5-0 polyester suture threads. After a 
three-month implantation in a canine MI model, they showed that LV remodeling was attenuated, 
while both LV and right ventricular (RV) systolic functions were improved in the CSD group 
compared to control. Diastolic function was not disturbed by the support device and mitral 
regurgitation was consistently prevented [33]. Another group later compared the effects of early and 
sustained restraint utilizing either a biodegradable or permanent textile CSD, respectively. They 
found that the biodegradable devices were more effective than the nonbiodegradable materials in 
improving systolic function while preserving diastolic function [32]. 
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A biventricular CSD that simultaneously acted as a mechanical reinforcement device and a 
replenishable delivery system was first developed by Zhou [38], and termed active hydraulic 
ventricle supporting drug delivery system (ASD). As described by subsequent studies in the group, 
the ASD is a mesh-like device consisting of several hollow tubules which are interconnected but also 
have independent areas connected to external catheters. The hollow ASD tubes can be filled with 
various fluids to generate a pressure that will be transmitted to the epicardium. Additionally, the 
authors claim that a pneumatic pump can be attached externally with the ASD tubules and can 
deliver an adjustable and measurable optimized restraint at the beginning of therapy and as the heart 
shrinks during active reverse remodeling. Using the ASD, the group has claimed positive cardiac 
function effects in a rat MI model following repetitive delivery of Salvia miltiorrhiza [31] and bone 
marrow stem cells [30]. 
The use of soft robotics to manufacture implantable devices that can augment cardiac function 
was first introduced in 2016 by Roche et al. [39] and was continued by others [40,41]. Given the 
reported effects on initial mechanical reinforcement following MI, our group recently introduced a 
therapeutic paradigm in which a textile based soft robotic sleeve is implanted and allowed to 
biointegrate with the infarcted myocardium, providing mechanical reinforcement which will ideally 
limit LV dilation and downstream pathological remodeling. After the functional timeline for 
providing passive support has ended, the soft robotic sleeve would be coupled to the heart, then 
actuated to provide active augmentation of cardiac function [42]. 
3. Optimizing Left Ventricle Restraint Devices 
Two clinically approved LV restraint devices are the Myosplint (Myocor) and the CardioClasp 
(Cardioclasp, Inc.). These devices interact with the LV only and their implantation procedure, which 
consists in reshaping the LV, does not allow them to be used as post-MI therapies, likely due to the 
risk of rupturing the weakened ischemic region [5]. However, their efficacy as treatments of HF has 
been demonstrated in computational models, animal studies, and clinical trials. The Myocor 
Myosplint is comprised of two rigid pads connected through the LV cavity. By increasing the tension 
between the two epicardial pads, the enlarged LV is reshaped into a bilobular ventricle with 
decreased chamber radius, which results in decreased wall stress [43]. Typically, three Myosplints 
are implanted in a longitudinal (apex-to-base) line on the LV, and the tension is adjusted until the 
radius of each lobe is approximately 80% of the radius of the dilated LV cavity. Animal testing in a 
canine model of rapid pacing heart failure yielded dramatic attenuation of chamber dilation four 
weeks post-implantation but no major functional improvements were observed between the 
treatment and control groups [11,44]. Initial clinical evaluation of the Coapsys, a similar device also 
developed by Myocor for mitral regurgitation, was promising and led to the initiation of Randomized 
Evaluation of Surgical Treatment for Off-Pump Repair of the Mitral Valve (RESTOR-MV) which 
ultimately was suspended due to financial limitations. However, analysis on two year follow-up data 
showed improved survival and decreased adverse events compared to standard surgical techniques 
[45,46]. 
The CardioClasp is another device that aims to reduce LV dilation by reshaping. It consists of 
two rigid bars connected through the LV cavity by an adjustable tether [47]. The bars are supposed 
to mimic the natural contour of the heart and are secured in place in a longitudinal (apex-to-base) 
line on the anterior and posterior LV walls. The tether is used to bring together the anterior and 
posterior bars until 30% reduction of the initial diastolic dimension is seen. Although multiple studies 
studying the acute effects of the CardioClasp in a canine HF model report a decrease in wall stress, 
increase in fractional area of contraction, increased systolic contractility, and positive chamber 
geometrical changes all relevant but no definite beneficial functional outcomes [47–49]. 
3.1. Adjustability 
The group that developed the QVR and AMVR was the first to investigate whether ventricular 
restraint therapy was affecting both the RV and the LV in the same fashion and whether having the 
ability to adjust the level of restraint would positively change hemodynamic parameters [50]. In an 
Biomimetics 2019, 4, 7 9 of 21 
acute study with healthy sheep, they found that the RV responds to restraint therapy differently than 
the LV by applying increasing levels of restraint and measuring hemodynamic parameters 
separately. They reported that increasing restraint level results in a nearly linear rise in RV filling 
pressure and at higher levels of restraint only RV filling was impaired. To correlate this with long-
term outcomes, they simulated clinical restraint therapy in a sheep model of ischemic dilated 
cardiomyopathy with LV failure and showed that long-term restraint of the entire heart does not 
have any substantial impact on the RV [50]. In later years, they demonstrated that limiting restraint 
to the LV alone seems to be a superior therapeutic strategy given that it allows for a higher level of 
restraint before cardiac tamponade arises and for a potentially less invasive implantation procedure 
[14]. 
3.2. Adding Functionality 
Consistent with design optimization strategies for biventricular restraint; adding functionality, 
varying the duration of restraint, and using biomimetic materials are features that have been 
explored. For instance, Kalogerakos et al. [44] developed a band of shape memory alloy fibers that 
would contract when electric current flows, similar to myocardium, and relax when the current flow 
is interrupted with the vision that this device could be anchored around the heart to assist in the 
pumping function, while simultaneously preventing LV dilation. By limiting LV restraint to the first 
week post-infarction with a biodegradable poly(ethylene glycol) sebacate diacrylate (PEGSDA) 
hydrogel, Vilaeti et al. [16] concluded that short-term LV restraint ameliorated LV remodeling at two 
weeks. Such effects were associated with a favorable inflammatory and foreign body response in the 
infarcted and noninfarcted zone. Interestingly, this study also evaluated a polyanhydroglucuronic 
acid/PEGSDA scaffold implanted immediately after MI that wrapped around the whole heart. The 
latter approach yielded better functional effects and less remodeling compared to the LV-only 
PEGSDA hydrogel alone and they hypothesize this is because increased fibroblast infiltration in the 
noninfarcted zone was observed earlier with the scaffold around the whole heart than with the 
hydrogel on the LV alone. However, the group acknowledges that this warrants further exploration 
and long-term evaluation [16] prior to translation to the clinic. 
4. Computational Modeling 
Finite element analysis (FEA) has been used to study various types of ventricular constraint 
devices. Figure 2 illustrates some of these studies and demonstrates the range of complexity of the 
models. Jhun et al. [51], created a simplified LV model to show that increasing passive epicardial 
restraint effectively eliminated end-diastolic myofiber stress while also reducing ejection fraction. 
The biventricular FEA model investigating the Acorn CorCap CSD also showed similar results [52]. 
Although it is outside the scope of this work, it is worth noting that FEA models of endocardial patch 
placement, and their effect on myofiber stress have also been described [53,54]. 
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Figure 2. Finite element analysis (FEA)of ventricular support. (A) Three-dimensional FEA mesh of a 
dilated canine left ventricle (LV) in the unloaded state with a cross-sectional view of the interior cavity 
and wall (modified and reprinted from [51] with permission from Elsevier) . (B) Biventricular FEA 
model with LV in red and right ventricle (RV) in grey (yellow lines are fully constrained). The green 
shell elements represent the Acorn cardiac support device (white lines on outside represent fiber 
orientations). Modified and reprinted from [52], with permission from Elsevier. (C) The Coapsys 
model showing the double pad side of the device. Infarct regions are colored with red while the 
remote regions are colored with green, myofiber stress at end systole in the virtual Coapsys model, 
showing a reduction of stress (in the blue area) compared to the control. Modified and reprinted from 
[55], with permission from Elsevier. (D) Device filling (8 mL) altered both the geometry and strain in 
the basal region where the device was positioned. Modified and reprinted from [18], with permission 
from Elsevier. (E) Maximum principal strain distribution without any wrap (left), with the epicardial 
mesh wrap (middle), and with the film wrap (right). Encircled area indicates RV collapse. Modified 
and reprinted from [37], with permission from the American Association for the Advancement of 
Science.   
More sophisticated, patient-specific models were also used to study ventricular restraint devices. 
Carrick et al. [55] showed the mechanical benefit of the Coapsys. More recently, an FEA model created 
by Park et al. [37] examined the mechanical effect of cardiomyoplasty wraps on a rat heart. They 
showed that a full film wrap significantly reduced the ventricular compliance resulting in an elevated 
end diastolic pressure and decreased end diastolic volume while a mesh wrap only slightly altered 
the mechanical properties compared to the baseline. By incorporating fiber orientation derived from 
diffusion tensor imaging (DTI), Sack et al. [56], used a four-chamber human heart model to 
demonstrate the benefits of a left ventricular assist device on myocardial wall stress. To the best of 
our knowledge, no literature simulates local reinforcement therapeutic modalities discussed in the 
subsequent section utilizing FEA models. 
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5. Optimizing Local Reinforcement: Multifunctional, Biomimetic and Adjustable Devices 
5.1. Overview and Timing of Intervention 
Locally restraining the infarct region to prevent infarct expansion and post-MI remodeling using 
synthetic patches has been evaluated as early as 1999 [57]. In recent years, an abundance of studies 
report on the effect on cardiac function following implantation of cardiac patches, naturally derived 
or synthetic scaffolds, and devices mechanically reinforcing the infarct region. Chronic studies are 
summarized in Table 2. Some of these were originally intended to provide localized mechanical 
reinforcement; others were implanted primarily for the delivery of bioagents to the infarct region but 
their attachment to the epicardium simultaneously provides a mechanical effect. Because local infarct 
restraint intends to prevent infarct expansion most of which occurs early post-MI, the majority of 
scaffolds, patches and devices evaluated have been implanted immediately post-MI [17–19,42,58–62]. 
However, some groups have seen benefits in cardiac function upon patch implantation at latter 
timepoints post-MI [63–70] ranging from four days to 12 weeks (Figure 3). 
 
Figure 3. Side-by-side visualization of gross post-myocardial infarction (MI) left ventricular (LV) 
remodeling and intervention timing of epicardial devices/patches implantation. Illustration modified 
and reprinted from [71], with permission from Elsevier. IR: Infarct reinforcement; LVO: LV only 
restraint; WH: Whole heart restraint. 
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Table 2. Summary of chronic epicardial local reinforcement studies (those reviewed in [5] are not included).  
Animal Infarct/HF Model 
Follow-
Up 
Time 
Post-MI 
Restraint Device or 
Patch Material 
EDV ESV EF SV CO FS/FAS/WT dP/dt ESPVR Reference 
Male C57BL mice LAD ligation 14 days 
Medical polyester mesh 
or silicone patch 
        [42] 
Female Sprague 
Dawley rats 
LAD ligation 28 days 
Therepi (TPU and 
polycarbonate 
membrane) + rMSC 
paracrine factors 
  ↑   ↑ FS   [61] 
Sheep 
LCx ligation/ischemic 
mitral regurgitation 
16 
weeks 
Poly-mesh (polyester 
mesh containing 
polyacrylamide granules 
with outer border of 
polyester fabric) 
↓ ↓ 
↔ 
LVEF 
   ↔ ↑ Emax [69] 
Male Sprague 
Dawley rats 
LAD ligation 6 weeks 
PDMS-coated  
Dacron patch 
     ↓ infarct WT   [62] 
Male Sprague 
Dawley rats 
LAD ligation 2 weeks 
Polyaniline and phytic 
acid grown on 
micropatterned  
chitosan films 
↔ ↔    ↔ FS   [72] 
Male New Zealand 
white rabbits 
Left 
posterolateral/lateral 
coronary artery 
ligation 
6 weeks PLLA patch + GCSF ↓ ↓ ↑ ↑ ↑ ↑ FS   [68] 
Male CD1 mice LAD ligation 21 days Platelet fibrin patch   ↑   ↑ FS   [19] 
Rat LAD ligation 
14 
weeks 
Inactivated  
SIS-ECM patch 
↓  ↑   ↑ WT 
(dP/dT)/LVEDV 
↑ 
↑ [73] 
Female Lewis rats 
Proximal Left 
Coronary Artery 
ligation 
10 
weeks 
Biodegradable PECUU + 
isotropic ECM  
enriched layer 
     ↑ FAC   [66] 
Female Sprague 
Dawley rats 
LAD ligation 1 month 
Ca–alginate microsphere 
patch covered in chitosan 
sheet 
     ↑ FS   [63] 
Male Landrace pigs Ischemia reperfusion 6 weeks SIS-ECM patch ↔ ↔ ↔      [60] 
Male Mongrel dogs LAD ligation 8 weeks 
Longitudinally 
inextensible knitted 
polyester and bovine 
collagen patch 
↔ ↔    
↔ infarct 
WT 
  [59] 
Biomimetics 2019, 4, 7 13 of 21 
Male Fischer  
CDF rats 
LAD ligation 
16 
weeks 
bFGF-enhanced  
SIS-ECM patch 
↓  ↑     
↔ 
ESPVR 
and 
EDPVR 
[67] 
Male Sprague 
Dawley rats 
LAD ligation 6 weeks 
SWNT/gelatin hydrogel 
patch + neonatal rat 
cardiomyocytes 
  ↑   FS ↑ ↑  
[65] 
Gelatin hydrogel patch + 
neonatal rat 
cardiomyocytes 
  ↑   FS ↑   
Gelatin hydrogel patch + 
neonatal rat cardiac 
fibroblasts 
  ↑   FS ↑   
Female Sprague 
Dawley rats 
LAD ligation 5 weeks 
Biodegradable PG 
nanofibrous patch + 
rMSC 
↓ ↓ ↑   FS ↑   [64] 
Pigs LCx ligation 4 weeks 
Polypropylene mesh 
covering balloon catheter 
↑ ↑ ↑      [18] 
Female Wistar rats Cryo-injury of LV 8 weeks 
Chitosan–HYA/SF 
patches 
     ↑ WT, ↑ FS   [58] 
bFGF: Basic fibroblast growth factor; CO: Cardiac output; dP/dt: Rate of systolic pressure generation; Emax: End-systolic elastance; EDPVR: Slope of the end-diastolic 
pressure–volume relationship; EDV: End-diastolic volume; EF: Ejection fraction; ESPVR: Slope of the end-systolic pressure–volume relationship; ESV: End-systolic 
volume; FAS: Fractional area shortening; FS: Fractional shortening; GCSF: Granulocyte colony-stimulating factor; HYA: Hyaluronan; LAD: Left anterior descending 
coronary artery; LCx: Left circumflex artery; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; PECUU: Poly(ester carbonate 
urethane)urea; PDMS: Polydimethylsiloxane; PG: Poly(ε-caprolactone)/gelatin; PLLA: Poly-L-lactide; rMSC: Rat mesenchymal stem cells; ; SF: Silk fibroin; SIS-ECM: 
Small intestinal submucosal extracellular matrix; SV: Stroke volume; SWNT: Single-walled carbon nanotubes; TPU: Thermoplastic polyurethane; WT: Wall 
thickening. ↑: Increased; ↔: No change; ↓: Decreased. 
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5.2. Adding Functionality 
Due to increasing interest in the promise of cardiac regeneration over the last few decades, a 
multitude of studies have utilized tissue engineering patches or biological or synthetic matrices 
loaded with therapeutic agents while providing local mechanical reinforcement to the post-MI 
ventricle. For instance, Rodness et al. [63] observed that the implantation of a calcium–alginate 
microsphere patch, with and without vascular endothelial growth factor (VEGF) and restrained by a 
chitosan sheet four days following MI, yielded better cardiac function as compared to rats with only 
a chitosan sheet. This group also reported on the added benefit that including the delivery of 
bioagents can have in the revascularization of ischemic myocardium in addition to mechanical 
reinforcement. They observed that VEGF-loaded microsphere patches had a thicker scar with higher 
capillary density in the border zone as compared to rats without VEGF in the microsphere patch. 
One group has conducted studies utilizing a commercially available extracellular matrix (ECM) 
biomaterial patch procured from porcine small intestine submucosa, named CorMatrix–ECM 
(CorMatrix Cardiovascular, Inc.) for its intrinsic bioactive properties and as a carrier of bioagents. For 
instance, in one study, they enhance the CorMatrix–ECM patch with basic fibroblast growth factor 
(bFGF), a potent inhibitor of fibrosis, to study its effects on myocardial fibrosis, chamber dilation, and 
progression to heart failure in a rat MI model 16 weeks post-treatment. They report improved ejection 
fraction following treatment bFGF-enhanced CorMatrix–ECM patch when compared to the control 
group as well as a significant reduction in LV dilation when compared to both the control group and 
the nonenhanced CorMatrix–ECM patch, suggesting the addition of bFGF was beneficial [67]. On a 
different study, the group used an ischemia reperfusion porcine model to show that the application 
of a biologic ECM construct, such as the CorMatrix-ECM, significantly increases endogenous 
myocardial recovery and vasculogenesis [60]. They confirmed that bioactive properties within the 
acellular ECM biomaterial are essential for functional benefits and positive impacts on remodeling to 
be observed using a rat MI model [73]. Although the biological effect ECM patches impart on the 
damaged myocardium are discussed, further understanding of the mechanical impact these bioactive 
scaffolds provide could lead to the further optimization of this combined therapeutic strategy. 
Indeed, one study by D’Amore et al. [66], evaluated the incorporation of ECM bioactivity and specific 
mechanical patch anisotropy in a rat MI-model. They showed that the implantation of a bilayered 
scaffold with isotropic mechanics and a cardiac ECM-enriched layer mitigates adverse remodeling 
10 weeks post-MI by decreasing LV global mechanical compliance, mitigating scar formation and LV 
wall thinning, and promoting angiogenesis. 
In addition to delivering therapeutic proteins, epicardially placed synthetic and natural patches 
can be used as scaffolds to deliver cells, or act as scaffolds for transplanted cells, enabling delivery of 
paracrine factors to the infarcted heart. In one such study, researchers implanted an elastic, 
biodegradable cardiac patch made of poly(ε-caprolactone)/gelatin (PG) nanofibers and loaded with 
mesenchymal stem cells (MSCs) one week post-MI in rats [64]. The combination of the PG patch and 
MSCs effectively restricted expansion of the LV wall, reduced scar size, and increased the density of 
vessels at the infarct site after four weeks of implantation. Interestingly, they attribute the mechanical 
effects of limiting LV expansion to the PG nanofibrous patches and the cardiomyogenic and 
angiogenic effects they observe to the MSCs loaded in the patch. 
In order to address some of the limitations associated with the sustained delivery of biological 
agents and cell therapy to the epicardial surface, our group developed a replenishable reservoir that, 
when implanted into the epicardial surface following MI, improved cardiac function following the 
repeated administration of MSCs [61]. We observed that the implantation of the device itself without 
the delivery of MSCs also had a beneficial effect in cardiac function, likely because the materials used 
to construct the reservoir provided mechanical reinforcement at the infarct zone upon MI creation. 
Apart from the incorporation of biological therapy to cardiac patches, two different groups also 
utilized conductive nanomaterials to improve electrical implant integration and compatibility with 
the myocardium as well as cardiac function [17,65]. One of them, used single-walled carbon 
nanotubes (SWNTs) incorporated into gelatin hydrogel scaffolds for the construction of engineered 
cardiac tissues. They found that their tissues structurally integrate with the host myocardium 
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achieving a bidirectional migration of cells. Auxetic cardiac patches have also been developed, with 
tunable mechanical and conductive properties aiming to provide both mechanical reinforcement and 
allow electrical conduction to prevent arrhythmias [17]. 
5.3. Adjustability 
As with global restraint devices, an approach taken to optimize the local reinforcement of the 
infarct was to make the level of restraint adjustable to better understand how this parameter affects 
LV function and remodeling. In 2013, Koomalsingh et al. [18] used a device designed to produce the 
variable alteration of infarct stiffness and geometry made of a polypropelene mesh and inflatable 
balloon catheter. In a pig MI model, they showed that an optimized level of infarct restraint can limit 
adverse LV remodeling after MI. In 2018, Kataoka et al. [69] validated another adjustable device made 
of a polymer filled mesh with the objective to reverse LV remodeling and reduce ischemic mitral 
regurgitation (IMR) in a sheep model. At implantation eight weeks into IMR, the adjustment of the 
device was done such that IMR was minimized and in a chronic study the group showed that this 
initial mechanical reinforcement led to a reduction of end-systolic and diastolic LV volumes. Another 
group pursued a study to test if the minimally invasive delivery of an inflatable localized device to 
treat ICM was feasible [70]. Their device was made of a heavy-duty 2.5 × 2.5 cm neoprene rubber 
inflatable bladder that was positioned centrally within the infarct and then secured to the 
surrounding border zone myocardium with polypropylene mesh. They validated that a 
minithoracotomy insertion of such device in a pig model was possible and by providing active 
assistance to the infarct region showed dramatic improvements in systolic function using magnetic 
resonance imaging [70]. 
The aforementioned studies use patches, scaffolds, and devices localized to the infarct area to 
better limit LV remodeling with mechanical reinforcement in conjunction with biological therapy 
delivery or electrical coupling, and in some cases, with adjustable mechanical restraint. Purely 
biomechanical studies have also been conducted to isolate and elucidate how global and local heart 
mechanics alter scar composition, a key determinant of the degree of pathological remodeling. 
Recently, Caggiano et al. [62] tested how modulating the local mechanical environment of the infarct 
altered scar collagen turnover, accumulation, and alignment in a rat MI model. Using anisotropic 
Dacron patches that eliminated circumferential strain in the infarct, the group showed that scar 
collagen aligned parallel to the regional strain experienced. This preferential mechanical 
reinforcement did not reduce the collagen area fraction but lead to a significantly reduced LV wall 
thickness when compared to untreated controls. These findings call for the consideration of 
regulating regional mechanics at the infarct zone when optimizing infarct reinforcement approaches. 
6. Conclusions and Future Perspectives 
As described in this review, ventricular restraint and infarct reinforcement are promising 
therapeutic approaches that can reduce or prevent LV remodeling post-MI. Global, biventricular 
restraint was the first approach tested clinically and has been studied in detail. Adjustability 
incorporated in these devices is highly beneficial, as the optimal level of restraint required to provide 
mechanical reinforcement yet avoid restriction of filling and tamponade can change over time as the 
heart adapts post-therapy. Currently, devices that can quantify and adjust the level of restraint consist 
of simple, fluid-filled bladders. Potentially, with the advent of 3D printing and soft robotic 
techniques, we can achieve a higher fidelity biomimetic mechanical reinforcement that conforms to 
the heart, moves with the heart wall, and has adaptable mechanical properties that can be tuned and 
adjusted over time. Using soft robotics, we could also achieve a finer control over spatial regions of 
supporting structures, for example to provide variable stiffness or anisotropy to optimize regional 
mechanical benefit to the infarcted heart. These techniques increase the potential design space for 
smart, customized biventricular reinforcement. Of course, further study is warranted to see the level 
of improvement in functions enabled by this higher granularity, and how much clinical improvement 
would result. In terms of univentricular support, various studies corroborate the fact that the 
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ventricles respond differently to restraint. This further motivates the design of a smart, tunable device 
that that imparts different levels of restraint to each ventricle. 
In terms of local post-MI reinforcement, literature in recent years has largely focused on the 
implantation of cardiac patches or scaffolds that also exert a mechanical effect. While results are 
promising, tools for minimally invasive delivery are desirable to accelerate these strategies along the 
path to clinical translation. The use of anisotropic patches that control how the infarct area is 
mechanically deformed demonstrate the importance of the effect of the mechanical environment on 
scar structure and LV remodeling. To date, researchers have limited deformation in circumferential 
or apicobasal directions. Finer control over material anisotropy in reinforcing patches may enable 
studies with patches with anisotropic properties parallel or perpendicular to the epicardial fibers. 
Indeed, further study is necessary to fully understand how patient-specific reinforcement might yield 
optimal therapeutic effects. Incorporating high resolution imaging techniques and computational 
modeling to make patient-specific patches could help elucidate whether this level of customization 
leads to better functional effects post-MI or if a more global approach to mechanical intervention is 
sufficient to see functional benefits. For example, patches that include specific fiber orientation could 
be designed based on DTI data, and computational modeling, as described in this review, could aid 
with optimization of patch/device design. Indeed, in vivo tracking of structural changes in the infarct 
region and the surrounding tissue has been reported in various studies using DTI [74–77]. Combining 
temporally dependent fiber orientation data with FEA simulation could aid in the design, testing, 
and optimization of local and global reinforcement strategies. Finally, a polytherapeutic approach is 
likely the most beneficial for scar modulation post-MI. As described here, many studies have 
included biological or electrical functionality in addition to mechanical reinforcement and while 
results combining therapeutic strategies are promising, further study of clinically relevant scenarios 
where the impact of added patch/device functionality and adjustability can be quantified in terms of 
overall therapeutic effect are needed. Further study of the temporal sequence of these strategies, and 
their interplay, should be a focus of future work since it is likely that optimizing a combination of 
approaches will yield the highest clinical benefit. 
Funding: This research received no external funding.  
Acknowledgments: This material is based upon work supported by the National Science Foundation 
Graduate Research Fellowship Program to C.E.V. Any opinions, findings, and conclusions or 
recommendations expressed in this material are those of the author(s) and do not necessarily reflect 
the views of the National Science Foundation.  
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiuve, S.E.; 
Cushman, M.; Delling, F.N.; Deo, R.; et al. Heart disease and stroke statistics—2018 Update: A report from 
the American Heart Association. Circulation 2018, 137, e67–e492, doi:10.1161/CIR.0000000000000558. 
2. Pfeffer, M.A.; Braunwald, E. Ventricular remodeling after myocardial infarction: Experimental 
observations and clinical implications. Circulation 1990, 81, 1161–1172, doi:10.1161/01.CIR.81.4.1161. 
3. Kwon, M.H.; Cevasco, M.; Schmitto, J.D.; Chen, F.Y. Ventricular restraint therapy for heart failure: A 
review, summary of state of the art, and future directions. J. Thorac. Cardiovasc. Surg. 2012, 144, 771–777.e1, 
doi:10.1016/j.jtcvs.2012.06.014. 
4. Chachques, J.C.; Jegaden, O.; Mesana, T.; Glock, Y.; Grandjean, P.A.; Carpentier, A.F. Cardiac bioassist: 
Results of the French multicenter cardiomyoplasty study. Asian Cardiovasc. Thorac. Ann. 2009, 17, 573–580, 
doi:10.1177/0218492309349371. 
5. Clarke, S.A.; Ghanta, R.K.; Ailawadi, G.; Holmes, J.W. Cardiac restraint and support following myocardial 
infarction. In Stud Mechanobiol Tissue Eng Biomater; Springer-Verlag: Berlin/Heidelberg, Germany, 
2013/2014; pp. 15 and 169–206. 
6. Lee, L.S.; Ghanta, R.K.; Mokashi, S.A.; Coelho-Filho, O.; Kwong, R.Y.; Kwon, M.; Guan, J.; Liao, R.; Chen, 
F.Y. Optimized ventricular restraint therapy: Adjustable restraint is superior to standard restraint in an 
Biomimetics 2019, 4, 7 17 of 21 
 
ovine model of ischemic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2013, 145, 824–831, 
doi:10.1016/j.jtcvs.2012.05.018. 
7. Fomovsky, G.M.; MacAdangdang, J.R.; Ailawadi, G.; Holmes, J.W. Model-based design of mechanical 
therapies for myocardial infarction. J. Cardiovasc. Transl. Res. 2011, 4, 82–91, doi:10.1007/s12265-010-9241-3. 
8. Fomovsky, G.M.; Clark, S.A.; Parker, K.M.; Ailawadi, G.; Holmes, J.W. Anisotropic reinforcement of acute 
anteroapical infarcts improves pump function. Circ. Hear. Fail. 2012, 5, 515–522, 
doi:10.1161/CIRCHEARTFAILURE.111.965731. 
9. Hendriks, T.; Schurer, R.A.J.; Al Ali, L.; van Den Heuvel, A.F.M.; van der Harst, P. Left ventricular 
restoration devices post myocardial infarction. Heart Fail. Rev. 2018, doi:10.1007/s10741-018-9711-2 
10. Zhu, Y.; Matsumura, Y.; Wagner, W.R. Ventricular wall biomaterial injection therapy after myocardial 
infarction: Advances in material design, mechanistic insight and early clinical experiences. Biomaterials 
2017, 129, 37–53. 
11. Sabbah, H.N. The cardiac support device and the Myosplint: Treating heart failure by targeting left 
ventricular size and shape. Ann. Thorac. Surg. 2003, 75, S13–S19. 
12. Ghanta, R.K.; Rangaraj, A.; Umakanthan, R.; Lee, L.; Laurence, R.G.; Fox, J.A.; Bolman, R.M.; Cohn, L.H.; 
Chen, F.Y. Adjustable, physiological ventricular restraint improves left ventricular mechanics and reduces 
dilatation in an ovine model of chronic heart failure. Circulation 2007, 115, 1201–1210, 
doi:10.1161/CIRCULATIONAHA.106.671370. 
13. Klodell, C.T.; Aranda, J.M.; McGiffin, D.C.; Rayburn, B.K.; Sun, B.; Abraham, W.T.; Pae, W.E.; Boehmer, 
J.P.; Klein, H.; Huth, C. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. 
J. Thorac. Cardiovasc. Surg. 2008, 135, 188–195, doi:10.1016/j.jtcvs.2007.09.034. 
14. Mokashi, S.A.; Lee, L.S.; Schmitto, J.D.; Ghanta, R.K.; McGurk, S.; Laurence, R.G.; Bolman, R.M.; Cohn, 
L.H.; Chen, F.Y. Restraint to the left ventricle alone is superior to standard restraint. J. Thorac. Cardiovasc. 
Surg. 2013, 146, 192–197, doi:10.1016/j.jtcvs.2012.09.027. 
15. Raman, J. Management of Heart Failure, 2nd Edition; Volume 2: Surgical; Springer-Verlag: London, UK, 2016; 
pp. 284 
16. Vilaeti, A.D.; Dimos, K.; Lampri, E.S.; Mantzouratou, P.; Tsitou, N.; Mourouzis, I.; Oikonomidis, D.L.; 
Papalois, A.; Pantos, C.; Malamou-Mitsi, V.; et al. Short-term ventricular restraint attenuates post-infarction 
remodeling in rats. Int. J. Cardiol. 2013, 165, 278–284, doi:10.1016/j.ijcard.2011.08.036. 
17. Kapnisi, M.; Mansfield, C.; Marijon, C.; Guex, A.G.; Perbellini, F.; Bardi, I.; Humphrey, E.J.; Puetzer, J.L.; 
Mawad, D.; Koutsogeorgis, D.C.; et al. Auxetic cardiac patches with tunable mechanical and conductive 
properties toward treating myocardial infarction. Adv. Funct. Mater. 2018, 28, doi:10.1002/adfm.201800618. 
18. Koomalsingh, K.J.; Witschey, W.R.T.; McGarvey, J.R.; Shuto, T.; Kondo, N.; Xu, C.; Jackson, B.M.; Gorman, 
J.H.; Gorman, R.C.; Pilla, J.J. Optimized local infarct restraint improves left ventricular function and limits 
remodeling. Ann. Thorac. Surg. 2013, 95, 155–162, doi:10.1016/j.athoracsur.2012.08.056. 
19. Tang, J.; Vandergriff, A.; Wang, Z.; Hensley, M.T.; Cores, J.; Allen, T.A.; Dinh, P.-U.; Zhang, J.; Caranasos, 
T.G.; Cheng, K. A regenerative cardiac patch formed by spray painting of biomaterials onto the heart. Tissue 
Eng. Part C Methods 2017, 23, 146–155, doi:10.1089/ten.tec.2016.0492. 
20. Oz, M.C.; Konertz, W.F.; Kleber, F.X.; Mohr, F.W.; Gummert, J.F.; Ostermeyer, J.; Lass, M.; Raman, J.; Acker, 
M.A.; Smedira, N. Global surgical experience with the Acorn cardiac support device. J. Thorac. Cardiovasc. 
Surg. 2003, 126, 983–991, doi:10.1016/S0022-5223(03)00049-7. 
21. Power, J.M.; Raman, J.; Dornom, A.; Farish, S.J.; Burrell, L.M.; Tonkin, A.M.; Buxton, B.; Alferness, C.A. 
Passive ventricular constraint amends the course of heart failure: A study in an ovine model of dilated 
cardiomyopathy. Cardiovasc. Res. 1999, 44, 549–555, doi:10.1016/S0008-6363(99)00255-2. 
22. Power, J.M.; Raman, J.; Byrne, M.J.; Alferness, C.A. Efficacy of the Acorn cardiac support device in animals 
with heart failure secondary to high rate pacing. Heart Fail. Rev. 2005, 10, 117–123, doi:10.1007/s10741-005-
4639-8. 
23. Chaudhry, P.A.; Mishima, T.; Sharov, V.G.; Hawkins, J.; Alferness, C.; Paone, G.; Sabbah, H.N. Passive 
epicardial containment prevents ventricular remodeling in heart failure. Ann. Thorac. Surg. 2000, 70, 1275–
1280, doi:10.1016/S0003-4975(00)01755-0. 
24. Blom, A.S.; Mukherjee, R.; Pilla, J.J.; Lowry, A.S.; Yarbrough, W.M.; Mingoia, J.T.; Hendrick, J.W.; Stroud, 
R.E.; McLean, J.E.; Affuso, J.; et al. Cardiac support device modifies left ventricular geometry and 
myocardial structure after myocardial infarction. Circulation 2005, 112, 1274–1283, 
doi:10.1161/CIRCULATIONAHA.104.499202. 
Biomimetics 2019, 4, 7 18 of 21 
 
25. Blom, A.S.; Pilla, J.J.; Arkles, J.; Dougherty, L.; Ryan, L.P.; Gorman, J.H.; Acker, M.A.; Gorman, R.C. 
Ventricular Restraint Prevents Infarct Expansion and Improves Borderzone Function After Myocardial 
Infarction: A study using magnetic resonance imaging, three-dimensional surface modeling, and 
myocardial tagging. Ann. Thorac. Surg. 2007, 84, 2004–2010, doi:10.1016/j.athoracsur.2007.06.062. 
26. Konertz, W.F.; Shapland, J.E.; Hotz, H.; Dushe, S.; Braun, J.P.; Stantke, K.; Kleber, F.X. Passive containment 
and reverse remodeling by a novel textile cardiac support device. Circulation 2001, 104 (Suppl. 1), I270–I275, 
doi:10.1161/hc37t1.094525. 
27. Oz, M.C.; Konertz, W.F.; Raman, J.; Kleber, F.X. Reverse remodeling of the failing ventricle: Surgical 
intervention with the Acorn cardiac support device. Congest. Hear. Fail. 2004, 10, 96–104, doi:10.1111/j.1527-
5299.2004.00291.x. 
28. Speziale, G.; Nasso, G.; Piancone, F.; Generali, K.; Paterno, C.; Miccoli, A.; Fiore, F.; Del Prete, A.; Del Prete, 
G.; Lopriore, V.; et al. One-year results after implantation of the CorCap for dilated cardiomyopathy and 
heart failure. Ann. Thorac. Surg. 2011, 91, 1356–1362, doi:10.1016/j.athoracsur.2011.02.006. 
29. Acker, M.A.; Jessup, M.; Bolling, S.F.; Oh, J.; Starling, R.C.; Mann, D.L.; Sabbah, H.N.; Shemin, R.; Kirklin, 
J.; Kubo, S.H. Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement 
stratum of the Acorn randomized trial. J. Thorac. Cardiovasc. Surg. 2011, 142, 569–574, 
doi:10.1016/j.jtcvs.2010.10.051. 
30. Yue, S.; Naveed, M.; Gang, W.; Chen, D.; Wang, Z.; Yu, F.; Zhou, X. Cardiac support device (ASD) delivers 
bone marrow stem cells repetitively to epicardium has promising curative effects in advanced heart failure. 
Biomed. Microdevices 2018, 20, doi:10.1007/s10544-018-0282-8. 
31. Naveed, M.; Wenhua, L.; Gang, W.; Mohammad, I.S.; Abbas, M.; Liao, X.; Yang, M.; Zhang, L.; Liu, X.; Qi, 
X.; et al. A novel ventricular restraint device (ASD) repetitively deliver Salvia miltiorrhiza to epicardium 
have good curative effects in heart failure management. Biomed. Pharmacother. 2017, 95, 701–710, 
doi:10.1016/j.biopha.2017.07.126. 
32. Kitahara, M.; Miyagawa, S.; Fukushima, S. Biodegradable versus non-biodegradable cardiac support 
device for treating ischemic cardiomyopathy in a canine heart. Semin. Thorac. Cardiovasc. Surg. 2017, 29, 51–
61. 
33. Okada, M.; Akita, T.; Mizuno, F.; Nakayama, A.; Morioka, K. Beneficial effects of a cardiac support device 
on left ventricular remodeling after posterior myocardial infarction: An evaluation by echocardiography, 
pressure–volume curves and ventricular histology. Surg. Today 2016, 46, 621–630, doi:10.1007/s00595-015-
1202-7. 
34. Magovern, J.A.; Teekell-Taylor, L.; Mankad, S.; Dasika, U.; McGregor, W.; Biederman, R.W.W.; Yamrozik, 
J.; Trumble, D.R. Effect of a flexible ventricular restraint device on cardiac remodeling after acute 
myocardial infarction. ASAIO J. 2006, 52, 196–200, doi:10.1097/01.mat.0000199751.51424.78. 
35. Ghanta, R.K.; Lee, L.S.; Umakanthan, R.; Laurence, R.G.; Fox, J.A.; Bolman, R.M.; Cohn, L.H.; Chen, F.Y. 
Real-time adjustment of ventricular restraint therapy in heart failure. Eur. J. Cardio-Thoracic. Surg. 2008, 34, 
1136–1140, doi:10.1016/j.ejcts.2008.07.013. 
36. Snowden, T.; Biswas, S.; Criscione, J. Modulation of diastolic filling using an epicardial diastolic recoil 
device. J. Med. Devices 2013, 7, 034503, doi:10.1115/1.4024156. 
37. Park, J.; Choi, S.; Janardhan, A.H.; Lee, S.Y.; Raut, S.; Soares, J.; Shin, K.; Yang, S.; Lee, C.; Kang, K.W.; et al. 
Electromechanical cardioplasty using a wrapped elasto-conductive epicardial mesh. Sci. Transl. Med. 2016, 
8, 1–12, doi:10.1126/scitranslmed.aad8568. 
38. Zhou, X. Active Hydraulic Ventricular Attaching Support System. U.S. Patent Application No. 9,089,425, 8 
May 2009. 
39. Roche, E.T.; Horvath, M.A.; Wamala, I.; Song, S.E.; Whyte, W.; Machaidze, Z.; Vasilyev, N.V.; Mooney, D.J.; 
Pigula, F.A.; Walsh, C.J. Soft robotic sleeve restores heart function. Sci. Transl. Med. 2017, 9, 3925, 
doi:10.1088/2053-1613/aa53b5. 
40. Payne, C.J.; Wamala, I.; Bautista-Salinas, D.; Saeed, M.; Van Story, D.; Thalhofer, T.; Horvath, M.A.; Abah, 
C.; del Nido, P.J.; Walsh, C.J.; et al. Soft robotic ventricular assist device with septal bracing for therapy of 
heart failure. Sci. Robot. 2017, 2, 6736, doi:10.1126/scirobotics.aan6736. 
41. Payne, C.J.; Wamala, I.; Abah, C.; Thalhofer, T.; Saeed, M.; Bautista-Salinas, D.; Horvath, M.A.; Vasilyev, 
N.V.; Roche, E.T.; Pigula, F.A.; et al. An Implantable Extracardiac Soft Robotic Device for the Failing Heart: 
Mechanical coupling and synchronization. Soft Robot. 2017, 4, doi:10.1089/soro.2016.0076. 
42. Horvath, M.A.; Varela, C.E.; Dolan, E.B.; Whyte, W.; Monahan, D.S.; Payne, C.J.; Wamala, I.A.; Vasilyev, 
Biomimetics 2019, 4, 7 19 of 21 
 
N.V.; Pigula, F.A.; Mooney, D.J.; et al. Towards alternative approaches for coupling of a soft robotic sleeve 
to the heart. Ann. Biomed. Eng. 2018, 46, 1534–1547, doi:10.1007/s10439-018-2046-2. 
43. McCarthy, P.M.; Takagaki, M.; Ochiai, Y.; Young, J.B.; Tabata, T.; Shiota, T.; Qin, J.X.; Thomas, J.D.; Mortier, 
T.J.; Schroeder, R.F.; et al. Device-based change in left ventricular shape: A new concept for the treatment 
of dilated cardiomyopathy. J. Thorac. Cardiovasc. Surg. 2001, 122, 482–490, doi:10.1067/mtc.2001.115240. 
44. Kalogerakos, P.D.; Hassoulas, J.; Ladopoulos, V.S. Beyond heart transplantation: Potentials and problems 
of the shape memory alloy fibers in the treatment of heart failure. ASAIO J. 2014, 60, 263–268, 
doi:10.1097/MAT.0000000000000054. 
45. Grossi, E.A.; Patel, N.; Woo, Y.J.; Goldberg, J.D.; Schwartz, C.F.; Subramanian, V.; Feldman, T.; Bourge, R.; 
Baumgartner, N.; Genco, C.; et al. Outcomes of the RESTOR-MV trial (Randomized Evaluation of a Surgical 
Treatment for Off-Pump Repair of the Mitral Valve). J. Am. Coll. Cardiol. 2010, 56, 1984–1993, 
doi:10.1016/j.jacc.2010.06.051. 
46. Mishra, Y.K.; Mittal, S.; Jaguri, P.; Trehan, N. Coapsys mitral annuloplasty for chronic functional ischemic 
mitral regurgitation: 1-Year results. Ann. Thorac. Surg. 2006, 81, 42–46, doi:10.1016/j.athoracsur.2005.06.023. 
47. Kashem, A.; Santamore, W.P.; Hassan, S.; Crabbe, D.L.; Margulies, K.B.; Melvin, D.B. CardioClasp: A new 
passive device to reshape cardiac enlargement. ASAIO J. 2002, doi:10.1097/00002480-200205000-00010. 
48. Kashem, A.; Hassan, S.; Crabbe, D.L.; Melvin, D.B.; Santamore, W.P.; Chitwood, W.R. Left ventricular 
reshaping: Effects on the pressure–volume relationship. J. Thorac. Cardiovasc. Surg. 2003, 125, 391–399, 
doi:10.1067/mtc.2003.4. 
49. Kashem, A.; Santamore, W.P.; Hassan, S.; Melvin, D.B.; Crabbe, D.L.; Margulies, K.B.; Goldman, B.I.; Llort, 
F.; Krieger, C.; Lesniak, J. CardioClasp changes left ventricular shape acutely in enlarged canine heart. J. 
Card. Surg. 2003, 18, S49–S60. 
50. Lee, L.S.; Ghanta, R.K.; Mokashi, S.A.; Coelho-Filho, O.; Kwong, R.Y.; Bolman, R.M.; Chen, F.Y. Ventricular 
restraint therapy for heart failure: The right ventricle is different from the left ventricle. J. Thorac. Cardiovasc. 
Surg. 2010, 139, 1012–1018, doi:10.1016/j.jtcvs.2009.09.064. 
51. Jhun, C.-S.; Wenk, J.F.; Zhang, Z.; Wall, S.T.; Sun, K.; Sabbah, H.N.; Ratcliffe, M.B.; Guccione, J.M. Effect of 
adjustable passive constraint on the failing left ventricle: A finite-element model study. Ann. Thorac. Surg. 
2010, 89, 132–137, doi:10.1016/j.athoracsur.2009.08.075. 
52. Wenk, J.F.; Ge, L.; Zhang, Z.; Mojsejenko, D.; Potter, D.D.; Tseng, E.E.; Guccione, J.M.; Ratcliffe, M.B. 
Biventricular finite element modeling of the Acorn CorCap cardiac support device on a failing heart. Ann. 
Thorac. Surg. 2013, 95, 2022–2027, doi:10.1016/j.athoracsur.2013.02.032. 
53. Sun, K.; Zhang, Z.; Suzuki, T.; Wenk, J.F.; Stander, N.; Einstein, D.R.; Saloner, D.A.; Wallace, A.W.; 
Guccione, J.M.; Ratcliffe, M.B. Dor procedure for dyskinetic anteroapical myocardial infarction fails to 
improve contractility in the border zone. J. Thorac. Cardiovasc. Surg. 2010, 140, 233–239, 
doi:10.1016/j.jtcvs.2009.11.055. 
54. Pantoja, J.L.; Zhang, Z.; Tartibi, M.; Sun, K.; Macmillan, W.; Guccione, J.M.; Ge, L.; Ratcliffe, M.B. Residual 
stress impairs pump function after surgical ventricular remodeling: A finite element analysis. Ann. Thorac. 
Surg. 2015, 100, 21982205–, doi:10.1016/j.athoracsur.2015.05.119. 
55. Carrick, R.; Ge, L.; Lee, L.C.; Zhang, Z.; Mishra, R.; Axel, L.; Guccione, J.M.; Grossi, E.A.; Ratcliffe, M.B. 
Patient-specific finite element-based analysis of ventricular myofiber stress after Coapsys: Importance of 
residual stress. Ann. Thorac. Surg. 2012, 93, 19641971–, doi:10.1016/j.athoracsur.2012.03.001. 
56. Sack, K.L.; Baillargeon, B.; Acevedo-Bolton, G.; Genet, M.; Rebelo, N.; Kuhl, E.; Klein, L.; Weiselthaler, G.M.; 
Burkhoff, D.; Franz, T.; et al. Partial LVAD restores ventricular outputs and normalizes LV but not RV 
stress distributions in the acutely failing heart in silico. Int. J. Artif. Organs 2016, 39, 421–430, 
doi:10.5301/ijao.5000520. 
57. Kelley, S.T.; Malekan, R.; Gorman, J.H.; Jackson, B.M.; Gorman, R.C.; Suzuki, Y.; Plappert, T.; Bogen, D.K.; 
St. John Sutton, M.G.; Edmunds, L.H. Restraining infarct expansion preserves left ventricular geometry 
and function after acute anteroapical infarction. Circulation 1999, 99, 135–142, doi:10.1161/01.CIR.99.1.135. 
58. Chi, N.H.; Yang, M.C.; Chung, T.W.; Chou, N.K.; Wang, S.S. Cardiac repair using chitosan-hyaluronan/silk 
fibroin patches in a rat heart model with myocardial infarction. Carbohydr. Polym. 2013, 92, 591–597, 
doi:10.1016/j.carbpol.2012.09.012. 
59. Clarke, S.A.; Goodman, N.C.; Ailawadi, G.; Holmes, J.W. Effect of scar compaction on the therapeutic 
efficacy of anisotropic reinforcement following myocardial infarction in the dog. J. Cardiovasc. Transl. Res. 
2015, 8, 353–361, doi:10.1007/s12265-015-9637-1. 
Biomimetics 2019, 4, 7 20 of 21 
 
60. Mewhort, H.E.M.; Turnbull, J.D.; Satriano, A.; Chow, K.; Flewitt, J.A.; Andrei, A.C.; Guzzardi, D.G.; 
Svystonyuk, D.A.; White, J.A.; Fedak, P.W.M. Epicardial infarct repair with bioinductive extracellular 
matrix promotes vasculogenesis and myocardial recovery. J. Hear. Lung Transplant. 2016, 35, 661–670, 
doi:10.1016/j.healun.2016.01.012. 
61. Whyte, W.; Roche, E.T.; Varela, C.E.; Mendez, K.; Islam, S.; O’Neill, H.; Weafer, F.; Shirazi, R.N.; Weaver, 
J.C.; Vasilyev, N.V.; et al. Sustained release of targeted cardiac therapy with a replenishable implanted 
epicardial reservoir /692/4019/2773 /639/301/54/152 /14/5 /14/35 /14/63 /59/5 /96/106 /96/100 /96/34 article. 
Nat. Biomed. Eng. 2018, 2, 416–428, doi:10.1038/s41551-018-0247-5. 
62. Caggiano, L.R.; Lee, J.-J.; Holmes, J.W. surgical reinforcement alters collagen alignment and turnover in 
healing myocardial infarcts. Am. J. Physiol. Circ. Physiol. 2018, 315, doi:10.1152/ajpheart.00088.2018. 
63. Rodness, J.; Mihic, A.; Miyagi, Y.; Wu, J.; Weisel, R.D.; Li, R.K. VEGF-loaded microsphere patch for local 
protein delivery to the ischemic heart. Acta Biomater. 2016, 45, 169–181, doi:10.1016/j.actbio.2016.09.009. 
64. Kai, D.; Wang, Q.L.; Wang, H.J.; Prabhakaran, M.P.; Zhang, Y.; Tan, Y.Z.; Ramakrishna, S. Stem cell-loaded 
nanofibrous patch promotes the regeneration of infarcted myocardium with functional improvement in rat 
model. Acta Biomater. 2014, 10, 2727–2738, doi:10.1016/j.actbio.2014.02.030. 
65. Zhou, J.; Chen, J.; Sun, H.; Qiu, X.; Mou, Y.; Liu, Z.; Zhao, Y.; Li, X.; Han, Y.; Duan, C.; et al. Engineering 
the heart: Evaluation of conductive nanomaterials for improving implant integration and cardiac function. 
Sci. Rep. 2014, 4, 1–11, doi:10.1038/srep03733. 
66. D’Amore, A.; Yoshizumi, T.; Luketich, S.K.; Wolf, M.T.; Gu, X.; Cammarata, M.; Hoff, R.; Badylak, S.F.; 
Wagner, W.R. Bi-layered polyurethane—Extracellular matrix cardiac patch improves ischemic ventricular 
wall remodeling in a rat model. Biomaterials 2016, 107, 1–14, doi:10.1016/j.biomaterials.2016.07.039. 
67. Mewhort, H.E.M.; Turnbull, J.D.; Meijndert, H.C.; Ngu, J.M.C.; Fedak, P.W.M. Epicardial infarct repair with 
basic fibroblast growth factor-enhanced CorMatrix-ECM biomaterial attenuates postischemic cardiac 
remodeling. J. Thorac. Cardiovasc. Surg. 2014, 147, 1650–1659, doi:10.1016/j.jtcvs.2013.08.005. 
68. Spadaccio, C.; Nappi, F.; De Marco, F.; Sedati, P.; Taffon, C.; Nenna, A.; Crescenzi, A.; Chello, M.; 
Trombetta, M.; Gambardella, I.; et al. Implantation of a poly-L-lactide GCSF-functionalized scaffold in a 
model of chronic myocardial infarction. J. Cardiovasc. Transl. Res. 2017, 10, 47–65, doi:10.1007/s12265-016-
9718-9. 
69. Kataoka, A.; Zeng, X.; Guerrero, J.L.; Kozak, A.; Braithwaite, G.; Levine, R.A.; Vlahakes, G.J.; Hung, J. 
Application of polymer-mesh device to remodel left ventricular–mitral valve apparatus in ischemic mitral 
regurgitation. J. Thorac. Cardiovasc. Surg. 2018, 155, 1485–1493, doi:10.1016/j.jtcvs.2017.11.006. 
70. McGarvey, J.R.; Shimaoka, T.; Takebayashi, S.; Aoki, C.; Kondo, N.; Takebe, M.; Zsido, G.A.; Jassar, A.; 
Gorman, J.H.; Pilla, J.J.; et al. Minimally invasive delivery of a novel direct epicardial assist device in a 
porcine heart failure model. Innov. Technol. Tech. Cardiothorac. Vasc. Surg. 2014, 9, 16–21, 
doi:10.1097/IMI.0000000000000049. 
71. Konstam, M.A.; Kramer, D.G.; Patel, A.R.; Maron, M.S.; Udelson, J.E. Left ventricular remodeling in heart 
failure: Current concepts in clinical significance and assessment. JACC Cardiovasc. Imaging 2011, 4, 98–108, 
doi:10.1016/j.jcmg.2010.10.008. 
72. Mewhort, H.E.M.; Svystonyuk, D.A.; Turnbull, J.D.; Teng, G.; Belke, D.D.; Guzzardi, D.G.; Park, D.S.; Kang, 
S.; Hollenberg, M.D.; Fedak, P.W.M. Bioactive extracellular matrix scaffold promotes adaptive cardiac 
remodeling and repair. JACC Basic Transl. Sci. 2017, 2, 450–464, doi:10.1016/j.jacbts.2017.05.005. 
73. Nguyen, C.T.; Dawkins, J.; Bi, X.; Marbán, E.; Li, D. Diffusion tensor cardiac magnetic resonance reveals 
exosomes from cardiosphere-derived cells preserve myocardial fiber architecture after myocardial 
infarction. JACC Basic to Transl. Sci. 2018, 3, 97–109, doi:10.1016/j.jacbts.2017.09.005. 
74. Wu, M.-T.; Su, M.-Y.M.; Huang, Y.-L.; Chiou, K.-R.; Yang, P.; Pan, ; Huay-Ben; Reese, T.G.; Wedeen, V.J.; 
Tseng, W.-Y.I. sequential changes of myocardial microstructure in patients postmyocardial infarction by 
diffusion-tensor cardiac MR correlation with left ventricular structure and function. Circ. Cardiovasc. 
Imaging 2009, 2, 32–40, doi:10.1161/CIRCIMAGING.108.778902. 
75. Wu, E.X.; Wu, Y.; Nicholls, J.M.; Wang, J.; Liao, S.; Zhu, S.; Lau, C.-P.; Tse, H.-F. MR diffusion tensor 
imaging study of postinfarct myocardium structural remodeling in a porcine model. Magn. Reson. Med. 
2007, 58, 687–695, doi:10.1002/mrm.21350. 
76. Wu, M.T.; Tseng, W.Y.; Su, M.Y.; Liu, C.P.; Chiou, K.R.; Wedeen, V.J.; Reese, T.G.; Yang, C.F. Diffusion 
tensor magnetic resonance imaging mapping the fiber architecture remodeling in human myocardium after 
infarction correlation with viability and wall motion. Circulation 2006, 114, 1036–1045, 
Biomimetics 2019, 4, 7 21 of 21 
 
doi:10.1161/CIRCULATIONAHA.105.545863. 
77. Sack, K.L.; Aliotta, E.; Choy, J.S.; Ennis, D.B.; Davies, N.H.; Franz, T.; Kassab, G.S.; Guccione, J.M. Effect of 
intra-myocardial Algisyl-LVRTM injectates on fibre structure in porcine heart failure. J. Mech. Behav. Biomed. 
Mater. 2018, 87, 172–179, doi:10.1016/J.JMBBM.2018.07.005. 
© 2019 by the authors. Submitted for possible open access publication under the terms 
and conditions of the Creative Commons Attribution (CC BY) license 
(http://creativecommons.org/licenses/by/4.0/). 
